#United States #Glioblastoma #Mountain View #Cordance Medical #EXACT Therapeutics

Promising Data from Cordance Medical and EXACT Therapeutics in Brain Cancer Research

In a groundbreaking development, Cordance Medical, known for its non-invasive technologies aimed at treating brain diseases, has teamed up with EXACT Therapeutics, a clinical-stage precision medicine firm. Together, they have revealed encouraging initial findings indicating a notable increase in the uptake of a radiopharmaceutical in mice with glioblastoma, one of the most aggressive forms of brain cancer. The results, which demonstrate an impressive increase ranging from 127% to 145%, were achieved by combining Exact Therapeutics’ Acoustic Cluster Therapy (ACT®) with a unique non-invasive ultrasound energy delivery device created by Cordance Medical.

This collaborative study was conducted at The Arctic University of Norway and the University Hospital North-Norway by Dr. Mathias Kranz. The combination of the ACT® technology and Cordance’s ultrasound device holds immense potential for accessing extensive areas of the brain. It facilitates the enhancement of therapeutic agent uptake and temporarily eases the permeability of the blood-brain barrier in targeted regions. The implications of this technology are vast, extending to both diagnostic and therapeutic applications in various brain diseases.

Dr. Bhaskar Ramamurthy, the co-founder and CEO of Cordance Medical, stated, "The integration of Cordance's technology alongside Exact's ACT® technology unlocks exciting avenues for accessing and influencing larger brain volumes without the need to increase the duration of the ultrasound procedure or the overall energy applied."

These promising results provide further validation of ACT® microcluster technology’s versatility in cancer therapy. Dr. Per Walday, CEO of EXACT Therapeutics, emphasized, "The positive outcomes in glioblastoma reinforce the adaptability of our non-invasive ACT® technology in oncology. We currently focus on oncology, particularly highlighted by our Phase 2 trial on locally advanced pancreatic cancer that secured IND clearance at the end of 2024."

Both companies are committed to advancing their research. More experiments will be conducted to bolster preliminary findings, with the intention to publish these results in reputable scientific journals. This collaboration showcases the potential for innovative treatments that could lead to better patient outcomes in the future.

About Cordance Medical

Cordance Medical is at the forefront of developing innovative, non-invasive solutions tailored for the treatment of brain diseases. Their flagship NeuroAccess™ platform is engineered to provide precise and targeted treatment options, aiming to enhance patient outcomes globally. For further details, please visit Cordance Medical.

About Exact Therapeutics

EXACT Therapeutics specializes in precision medicine, employing ultrasound and microbubble technology to enable targeted drug delivery in oncology. The pioneering Acoustic Cluster Therapy (ACT®) is designed to enhance the efficacy of a variety of therapeutic agents across numerous applications, including those related to brain health. Explore more at Exact Therapeutics.